158 related articles for article (PubMed ID: 31562954)
1. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma.
Pottoo FH; Barkat MA; Harshita ; Ansari MA; Javed MN; Sajid Jamal QM; Kamal MA
Semin Cancer Biol; 2021 Feb; 69():100-108. PubMed ID: 31562954
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.
Ansari MA; Thiruvengadam M; Farooqui Z; Rajakumar G; Sajid Jamal QM; Alzohairy MA; Almatroudi A; Alomary MN; Chung IM; Al-Suhaimi EA
Semin Cancer Biol; 2021 Feb; 69():109-128. PubMed ID: 31891780
[TBL] [Abstract][Full Text] [Related]
3. MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.
Beckers A; Van Peer G; Carter DR; Mets E; Althoff K; Cheung BB; Schulte JH; Mestdagh P; Vandesompele J; Marshall GM; De Preter K; Speleman F
Oncotarget; 2015 Mar; 6(7):5204-16. PubMed ID: 25294817
[TBL] [Abstract][Full Text] [Related]
4. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
[TBL] [Abstract][Full Text] [Related]
5. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
7. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
[TBL] [Abstract][Full Text] [Related]
8. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH; Horn S; Otto T; Samans B; Heukamp LC; Eilers UC; Krause M; Astrahantseff K; Klein-Hitpass L; Buettner R; Schramm A; Christiansen H; Eilers M; Eggert A; Berwanger B
Int J Cancer; 2008 Feb; 122(3):699-704. PubMed ID: 17943719
[TBL] [Abstract][Full Text] [Related]
9. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
10. The roles of microRNAs in neuroblastoma.
Mei H; Lin ZY; Tong QS
World J Pediatr; 2014 Feb; 10(1):10-6. PubMed ID: 24464658
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
12. RNA N
Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
[TBL] [Abstract][Full Text] [Related]
13. N-myc and noncoding RNAs in neuroblastoma.
Buechner J; Einvik C
Mol Cancer Res; 2012 Oct; 10(10):1243-53. PubMed ID: 22936790
[TBL] [Abstract][Full Text] [Related]
14. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
[No Abstract] [Full Text] [Related]
15. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.
Bettinsoli P; Ferrari-Toninelli G; Bonini SA; Prandelli C; Memo M
BMC Cancer; 2017 May; 17(1):352. PubMed ID: 28525978
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme.
Pottoo FH; Javed MN; Rahman JU; Abu-Izneid T; Khan FA
Semin Cancer Biol; 2021 Feb; 69():391-398. PubMed ID: 32302695
[TBL] [Abstract][Full Text] [Related]
17.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Role of MicroRNAs in Neuroblastoma.
Veeraraghavan VP; Jayaraman S; Rengasamy G; Mony U; Ganapathy DM; Geetha RV; Sekar D
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011335
[TBL] [Abstract][Full Text] [Related]
19. microRNA‑202 suppresses MYCN expression under the control of E2F1 in the neuroblastoma cell line LAN‑5.
Li YG; He JH; Yu L; Hang ZP; Li W; Shun WH; Huang GX
Mol Med Rep; 2014 Feb; 9(2):541-6. PubMed ID: 24337320
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
